Semaglutide vs liraglutide: what the head-to-head trials actually show

Liraglutide and semaglutide are both GLP-1 receptor agonists from Novo Nordisk, and they are often discussed as if they were interchangeable. They are not. Liraglutide is the older molecule, dosed once daily; semaglutide is the newer one, dosed once weekly and, by the direct evidence, more potent. The honest comparison rests on two randomized trials that actually put the two drugs head-to-head — one in weight management, one in type 2 diabetes. Here is what they show.

Same class, different molecules

Both drugs are GLP-1 receptor agonists, so they work through the same core mechanism — enhancing glucose-dependent insulin secretion and slowing gastric emptying while reducing appetite. The practical differences are structural and pharmacokinetic. Liraglutide has a shorter half-life and must be injected once daily. Semaglutide was engineered for a much longer half-life and is injected once weekly (Rybelsus is a separate daily oral tablet form). That difference in exposure, along with the higher doses semaglutide reaches, is the practical reason the direct trials favor it on magnitude.

The head-to-head for weight: STEP 8

For weight loss, the direct comparison is the STEP 8 randomized trial. Adults with overweight or obesity and without diabetes were assigned to once-weekly semaglutide 2.4 mg or once-daily liraglutide 3.0 mg (the Saxenda dose). Over 68 weeks, semaglutide produced a mean body-weight change of about −15.8% versus about −6.4% for liraglutide — a clear, statistically significant advantage for the weekly drug, with a larger share of participants reaching the 10%, 15% and 20% loss thresholds.^[1] This is the single cleanest piece of evidence on the weight question, because both drugs were used at their approved obesity doses in the same population. The two weight formulations are compared in more detail in our Wegovy versus Saxenda breakdown, and the broader semaglutide dataset in the semaglutide weight-loss trials.

The head-to-head for diabetes: SUSTAIN 10

In type 2 diabetes, the direct comparison is SUSTAIN 10. Patients on background oral therapy were randomized to once-weekly semaglutide 1.0 mg or once-daily liraglutide 1.2 mg. Over 30 weeks, semaglutide lowered HbA1c more (roughly −1.7% versus about −1.0%) and produced greater weight loss than liraglutide.^[2] One caveat matters for reading this fairly: the trial used liraglutide 1.2 mg, the lower of its two diabetes doses, not the 1.8 mg maximum — so the comparison is not against liraglutide at full diabetes strength. Even so, the direction is consistent with the weight data: at the doses tested, weekly semaglutide outperformed daily liraglutide.

Side-by-side

Where liraglutide still fits

"More potent" is not the same as "always the right choice." Liraglutide has a longer real-world track record, a daily injection that some patients titrate and tolerate more gradually, and its own approved indications. Both drugs carry the same GLP-1 side-effect profile — predominantly gastrointestinal (nausea, diarrhea, vomiting) — so tolerability is driven more by the individual and the escalation schedule than by which molecule it is. Cost, insurance coverage and supply have also shifted which drug is actually accessible at different times. For the semaglutide brand distinctions specifically, see Ozempic versus Wegovy, and for how semaglutide stacks up against the dual agonist, our tirzepatide versus semaglutide comparison.

The honest bottom line

On the two questions where the drugs were compared directly — weight loss (STEP 8) and glycemic control (SUSTAIN 10) — once-weekly semaglutide produced larger effects than once-daily liraglutide at the doses tested. That makes semaglutide the more potent option on average and, for many, the more convenient one. But the choice between them is still individual: dosing preference, tolerability, formulation, indication and access all legitimately shift the answer. Use the head-to-head trials for what they establish — relative magnitude — not as a blanket verdict for every patient.